

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application No.	10/524,945
				Filing Date	2/16/05 (PCT priority: 8/28/03)
				First Named Inventor	Farhad PARHAMI
				Art Unit	1633 (conf. 3129)
				Examiner Name	Maria Gomez LEAVITT
Sheet	1	of	2	Attorney Docket No.	58086-241892

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1	US 2003/0153541	8/14/03	Dudley <i>et al.</i>	
	A2	US 2004/235739	11/25/04	Mahanthappa	
	A3	US 2005/0095677	5/5/05	Liu <i>et al.</i>	
	A4	US 5,929,062	7/27/99	Haines	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B1	GB 2 320 190	6/17/98	Chein		
	B2	WO 1997/040137	10/30/97	Osiris Therapeutics Inc		
	B3	WO 2000/054759	9/21/00	Tularik Inc		
	B4	WO 2001/015676	3/8/01	Xenon Genetics		
	B5	WO 2002/080952	10/17/02	Lorantis Limited		
	B6	WO 2005/028616	3/31/05	Caritas St. Elizabeth's Medical Center of Boston		
	B7	WO 2006/110490	10/19/06	UCLA		
	B8	WO 2007/028101	3/8/07	UCLA		
	B9	WO 2008/115469	9/25/08	UCLA		

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Aghaloo <i>et al.</i> ; Oxysterols enhance osteoblast differentiation in vitro and bone healing in vivo; J. Bone & Mineral Research 2005, 20(9): S361, Abstract M203, 27th Annual Meeting of American Society for Bone and Mineral Research	
	C2	Choo <i>et al.</i> , Otolaryngology Head Neck Surgery 1999, 120: 84-91	
	C3	European Search Report in 241907 EP mailed 6/15/09 (EP 03749213.9)	
	C4	European Search Report in 256918 EP mailed 7/1/09 (suppl., EP 06824888.9)	
	C5	ISR for PCT/US06/012902 mailed 7/7/08	
	C6	ISR for PCT/US06/34374 mailed 6/16/08	
	C7	ISR for PCT/US07/016309 mailed 9/16/08	

Examiner Signature	/Maria Leavitt/	Date Considered	12/03/2009
-----------------------	-----------------	--------------------	------------

DC2/1032106

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ML/

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application No.	10/524,945
				Filing Date	2/16/05 (PCT priority: 8/28/03)
				First Named Inventor	Farhad PARHAMI
				Art Unit	1633 (conf. 3129)
				Examiner Name	Maria Gomez LEAVITT
Sheet	2	of	2	Attorney Docket No.	58086-241892

C8	ISR for PCT/US07/25833 mailed 9/11/08	
C9	ISR for PCT/US08/013319 mailed 4/8/09	
C10	Izumo N <i>et al.</i> ; Lipophilic statins can be osteogenic by promoting osteoblastic calcification in a Cbfa1- and BMP-2-independent manner. Methods and Findings in Experimental and Clinical Pharmacology 2001, 23(7): 389-394	
C11	Kadiyala <i>et al.</i> ; Culture expanded canine mesenchymal stem cells possess osteochondrogenic potential in vivo and in vitro; Cell Transplantation 1997, 6(2): 125-134	
C12	Lefevre A, Morera A-M, Saez JM. Adrenal cholesterol-binding protein: properties and partial purification. FEBS Letters 1978, 89(2): 287-292.	
C13	Mezey <i>et al.</i> , Oral Diseases 2009, Abstract	
C14	Mundy <i>et al.</i> ; Science 1999, 286: 1946-1949	
C15	Nakamura <i>et al.</i> ; Stimulation of bone formation by intraosseous application of recombinant basic fibroblast growth factor in normal and ovariectomized rabbits; J. Orthopaedic Research 1997, 15(2): 307-313	
C16	Office Action for 10/569,994 dated 1/2/09	
C17	Office Action for 10/569,994 dated 5/30/08	
C18	Office Action for 10/569,994 dated 8/31/09	
C19	Song <i>et al.</i> , Chinese Journal of Reparative and Reconstructive Surgery 2002, 16: 384-387	
C20	Written Opinion for PCT/US04/028162 mailed 2/22/05	
C21	Written Opinion for PCT/US06/012902 mailed 7/7/08	
C22	Written Opinion for PCT/US06/34374 mailed 6/16/08	
C23	Written Opinion for PCT/US07/016309 mailed 9/16/08	
C24	Written Opinion for PCT/US07/05073 mailed 10/29/07	
C25	Written Opinion for PCT/US08/013319 mailed 4/8/09	
C26	Yeh <i>et al.</i> , Journal of Cell Biochemistry 2002, 87: 292-304	
C27	Zhang <i>et al.</i> ; Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair; J. Clinical Investigation 2002, 109(11): 1405-1415	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached

Examiner Signature	/Maria Leavitt/	Date Considered	12/03/2009
--------------------	-----------------	-----------------	------------

DC2/1032106

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ML/